Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.

Lou E, Johnson M, Sima C, Gonzalez-Espinoza R, Fleisher M, Kris MG, Azzoli CG.

Cancer Biomark. 2014;14(4):207-14. doi: 10.3233/CBM-140399.


Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.

Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, Deangelis LM, Omuro A.

Neurology. 2013 Apr 23;80(17):1598-605; discussion 1603. doi: 10.1212/WNL.0b013e31828f183f. Epub 2013 Apr 3.


Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.

Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V, Fleisher M.

Clin Chem Lab Med. 2010 Feb;48(2):271-8. doi: 10.1515/CCLM.2010.066.


Determination of busulfan in human plasma using an ELISA format.

Courtney JB, Harney R, Li Y, Lundell G, McMillin GA, Agarwal G, Juenke JM, Mathew A, Gonzalez-Espinoza R, Fleisher M, Salamone SJ.

Ther Drug Monit. 2009 Aug;31(4):489-94. doi: 10.1097/FTD.0b013e3181a8c99c.


Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.

Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2009 Mar 15;15(6):2091-7. doi: 10.1158/1078-0432.CCR-08-2036. Epub 2009 Mar 10.


Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.

Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Väänänen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H.

Clin Chem. 2009 Apr;55(4):765-73. doi: 10.1373/clinchem.2008.117952. Epub 2009 Feb 20.


Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.

Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Dec 1;13(23):7053-8.


Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.

Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, Terstappen LW, Lilja H, Heller G, Fleisher M, Scher HI.

Clin Cancer Res. 2007 Apr 1;13(7):2023-9.

Supplemental Content

Loading ...
Support Center